Promaxo Holdings, Inc., a medical imaging, robotics, and AI technology company based in Oakland, California, announced the sale of eighteen systems during the second quarter ending June 30, 2023. This represented growth from fourteen systems sold in Q1 2023, with sales distributed across physician practices, ambulatory surgery centers, and integrated delivery networks.
Notable Q2 Sales
- SCA Health acquired their inaugural Promaxo system. The organization operates over 320 surgical facilities specializing in specialty care services.
- Urology America purchased their second and third systems as part of their multi-practice platform expansion across the U.S.
- KSK Cancer Center of Irvine acquired their first system, marking Promaxo’s entry into the cancer center market.
Growth Milestone
Since commencing commercial operations in Q4 2021, Promaxo has distributed 57 total systems across twenty states.
CEO Dr. Amit Vohra stated: “We are pleased to announce another quarter of solid execution” with “healthy growth in the adoption.”
Company Overview
The company develops single-sided MRI technology with AI-driven imaging, FDA-cleared for office-based prostate interventions. Promaxo maintains over 200 patents and focuses on minimally-invasive diagnostic and interventional solutions.